<DOC>
	<DOCNO>NCT02503436</DOCNO>
	<brief_summary>The main objective propose non-interventional study obtain real-world effectiveness , safety treatment pattern data patient BRCAm+ ( Breast Cancer Gene ( ) mutation positive ) platinum sensitive relapse ( PSR ) ovarian cancer German hospital outpatient practice treat olaparib .</brief_summary>
	<brief_title>C-PATROL - Non-interventional Study ( NIS ) Collect Clinical Patient Reported Outcome Data Olaparib Treated BRCAm+ PSR Ovarian Cancer Population</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Signed write informed consent Women age ≥ 18 year Patients platinum sensitive relapse high grade epithelial ovarian cancer ( include primary peritoneal and/or fallopian tube cancer ) . ( Platinum sensitive disease define disease progression ≥6 month completion last dose platinum base chemotherapy . Patients must currently response platinumbased chemotherapy . For last chemotherapy course immediately prior enrolment study , patient must , opinion investigator , response ( partial complete ) , follow completion chemotherapy course . Documented BRCA mutation ( germline and/or somatic mutation BRCA1 ( Breast Cancer gene 1 ) and/or BRCA2 ( Breast Cancer gene 2 ) predict deleterious suspect deleterious ( know predict detrimental/lead loss function ) ) Patients line specification mention German LYNPARZA ( olaparib ) SmPC ( Summary Product Characteristics ) Known hypersensitivity olaparib excipients drug Patients start olaparib monotherapy 14 day give informed consent Pregnancy breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ovarian Cancer , Fallopian Tube Cancer , primary peritoneal cancer , BRCA1 Gene , BRCA2 Gene</keyword>
</DOC>